Who are Intra thecal morphine.'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BENZHYDROCODONE, Nucynta, Alfenta, Dilaudid-Hp, Dilaudid-Hp, Sufenta Preservative Free.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intra-thecal-morphine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Intra thecal morphine. — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intra thecal morphine. (Intra thecal morphine.) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid agonist. Area: Pain Management.

marketed Opioid agonist Mu opioid receptor (μ-opioid receptor) Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Intra thecal morphine. (Intra thecal morphine.) — Ain Shams University. Intrathecal morphine is an opioid agonist that binds to mu opioid receptors in the spinal cord to block pain signal transmission.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Intra thecal morphine. TARGET	Intra thecal morphine.	Ain Shams University	marketed	Opioid agonist	Mu opioid receptor (μ-opioid receptor)
BENZHYDROCODONE	BENZHYDROCODONE		marketed	Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic	Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways	2018-01-01
Nucynta	TAPENTADOL	Collegium Pharm Inc	marketed	Opioid Agonist	Mu-type opioid receptor	2008-01-01
Alfenta	ALFENTANIL	Rising	marketed	Opioid Agonist	Mu-type opioid receptor	1986-01-01
Dilaudid-Hp	HYDROMORPHONE	Fresenius Kabi	marketed	Opioid Agonist	mu-opioid receptor	1984-01-01
Dilaudid-Hp	Hydromorphone Hydrochloride	Fresenius Kabi	marketed	Opioid agonist	Mu-opioid receptor	1984-01-01
Sufenta Preservative Free	SUFENTANIL	Rising	marketed	Opioid Agonist	Mu-type opioid receptor	1984-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid agonist class)

University of British Columbia · 3 drugs in this class
Ciusss de L'Est de l'Île de Montréal · 2 drugs in this class
Kaohsiung Veterans General Hospital. · 2 drugs in this class
Nycomed · 2 drugs in this class
Rigshospitalet, Denmark · 2 drugs in this class
University Hospital, Ghent · 2 drugs in this class
Fundación Universitaria de Ciencias de la Salud · 2 drugs in this class
Erasme University Hospital · 2 drugs in this class
Cephalon · 2 drugs in this class
Corporacion Parc Tauli · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intra thecal morphine. — Competitive Intelligence Brief. https://druglandscape.com/ci/intra-thecal-morphine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing